Yoshizaki, T., Kusunoki, C., Kondo, M., Yasuda, M., Kume, S., Morino, K., Sekine, O., Ugi, S., Uzu, T., Nishio, Y., Kashiwagi, A., Maegawa, H., 2012. Autophagy regulates inflammation in adipocytes. Biochem. Biophys. Res. Commun. 417, 352–357.

Zhou, Y., Damsky, C.H., Chiu, K., Roberts, J.M., Fisher, S.J., 1993. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. J. Clin. Invest. 91, 950–960.

Letter to the Editor

Whole exome sequencing revealed biallelic *IFT122* mutations in a family with CED1 and recurrent pregnancy loss

To the Editor:

Cranioectodermal dysplasia-1 (CED1), also known as Sensenbrenner syndrome (MIM 218330), is characterized by skeletal, craniofacial, and ectodermal abnormalities (1). Here, we report a family with CED1 and recurrent abortions.

I-2, 39-year-old woman, was referred to our hospital for consultation regarding recurrent abortions. Although she had one healthy boy (II-2), she suffered from two artificial abortions due to fetal hydrops at 13 weeks of gestation (II-1) and skeletal anomalies at 21 weeks of gestation (II-8), one intrauterine fetal death with hydrops at 13 weeks of gestation (II-7), and four recurrent miscarriages (II-3 at 6 weeks, II-4 at 8 weeks, II-5 at 8 weeks, and II-6 at 7 weeks) (Fig. 1a). Postmortem physical findings of II-8 included a skull deformity and blisters beside the nasal bridge due to obstetric intervention, low set ears, nuchal edema, a narrow thorax, and acromelic shortening of the limbs, posterior bowing of the lower legs and bilateral 2–3 toe syndactyly (Fig. 1b). Postmortem radiography and 3-D computed tomography showed generalized skeletal alterations which were thought to fit to CED1, though the sharp angulation of the tibiae was very unusual (Fig. 1b).

Exome sequencing was performed in I-2, II-2, and II-8 as previously described (2). We identified compound heterozygous mutations in *IFT122* in the fetal skeletal anomalies (II-8): c.1108delG (p.E370Sfs*51) in exon 11 and c.1636G>A (p.G546R) in exon 14 was inherited from his mother (Fig. 1c,d). Of note, we confirmed the same compound heterozygous mutations (c.1108delG: 2 of 29 clones, c.1636G>A: 13 of 30 clones) by capillary sequence of polymerase chain reaction (PCR) product from cloned DNA from paraffin-embedded chorionic villi (II-6) (Fig. 1e). Accordingly, c.1108delG found in II-6 and II-8 was presumed to be inherited from the father, though it was not directly confirmed.

Walczak-Sztulpa et al. reported homozygous missense mutations of *IFT122* in three patients from two consanguineous pedigrees with CED1: p.V553G in family CED-01, p.S373F in family CED-02, and compound heterozygous mutations, c.502+5G>A and p.W7C in one sporadic case, family CED-03 (1) (Fig. 1c). The four patients with *IFT122* mutations showed skeletal anomalies. We found compound heterozygous

mutations in a fetus with skeletal anomalies (II-8) and the villous tissues (II-6). Clinical skeletal features of the aborted fetus (II-8) are consistent with those of the reported CED patients carrying biallelic *IFT122* mutations. Because they were found in the villous tissues (II-6) that was sequenced, biallelic *IFT122* mutations may have caused some of the recurrent abortions in this family. All four *IFT122* missense mutations (including ours) are predicted to be damaging for IFT122 function (Table 1).

CED1 belongs to a group of short rib dysplasias, including Ellis van Creveld syndrome, Jeune asphyxiating thoracic dysplasia, short rib polydactyly syndrome (SRPS) I (Saldino-Noonan), SRPS II (Majewski), SRPS III (Verma-Naumoff) and SRPS IV (Beemer-Langer) (3). The skeletal manifestation of the present fetus shared some features with other short rib dysplasias. For example, humeral bowing resembles that commonly seen in Ellis van Creveld syndrome. Severe tibial angulation was somewhat reminiscent of tibial hypoplasia in SRPS II (Majewski type). Generally, CED1 is a non-lethal disorder. However, the present family showed recurrent abortions, which can be considered as the severest phenotypes caused by biallelic *IFT122* mutations in human. Interestingly, *Ift122*-null mice show multiple developmental defects with embryonic lethality consistent with recurrent pregnancy loss in our family (4).

On the basis of the assumption that recessive mutations may cause recurrent pregnancy loss, the literatures have been carefully reviewed, but only a homozygous *HERG* mutation in a family were found to show recurrent intrauterine fetal loss (5).

In conclusion, we were able to find causative *IFT122* mutations in a non-consanguineous family with recurrent abortions. This information is useful for future counseling including preimplantatory diagnosis in this family.

Fig. 1. Clinical finding of fetal skeletal anomalies (II-8) and genetic studies. (a) Familial pedigree. II-1 and II-8 were artificially terminated, II-3, II-4, II-5, II-6 and II-7 were spontaneously aborted. * DNA was available. (b) Clinical photographs and 3D computed tomography of II-8. (i–v) Postmortem physical findings included a skull deformity due to obstetric intervention, blisters beside the nasal bridge, low set ears, nuchal edema, a narrow thorax, and acromelic shortening of the limbs, anterior bowing of the lower legs and bilateral 2–3 toe syndactyly. (vi–vii) Postmortem 3-D computed tomography showed generalized skeletal alterations. The thorax was narrow with short ribs. The lower ribs showed a wavy appearance. The spine and ilia were normal. The long bones were not apparently short. However, the humeri were medially bowed, and the tibiae showed sharp bending at their proximal part. Ossification of the proximal and middle phalanges was defective. (c) The gene structure of *IFT122* (upper) and its protein structure (lower) containing seven WD40 domains (blue). Mutations found in this family and in the previous report are depicted above and below the protein, respectively. (d) Sequence electropherogram of family members. Compound heterozygous mutations are indicated in II-8, while healthy members (I-2 and II-2) only carry one of the two mutations. (e) Sequence electropherogram of the villous tissue at 7 weeks of gestation (II-6). Amplified PCR products were cloned into pCR4-TOPO vector and each clone was subjected to sequencing. Compound heterozygous mutations are indicated.

593

Table 1. *IFT122* mutation and their pathogenicity prediction

Family; Ref.	Allele 1					Allele 2				
	Nucleotide change	Amino acid change	SIFT	PolyPhen-2	MutationTaster	Nucleotide change	Amino acid change	SIFT	PolyPhen-2	MutationTaster
CED-01; Walczak-Sztulpa et al. (1)	c.1658T>G	p.V553G	0.00; damaging	1.000; probably damaging	1.000; disease causing	c.1658T>G	p.V553G	0.00; damaging	1.000; probably damaging	1.000; disease causing
CED-02; Walczak-Sztulpa et al. (1)	c.1118C>T	p.S373F	0.00; damaging	1.000; probably damaging	1.000; disease causing	c.1118C>T	p.S373F	0.00; damaging	1.000; probably damaging	1.000; disease causing
CED-03; Walczak-Sztulpa et al. (1)	c.21G>C	p.W7C	0.00; damaging	1.000; probably damaging	1.000; disease causing	c.502+5G>A	Splice-site change	–	–	–
This study	c.1636G>A	p.G546R	0.00; damaging	1.000; probably damaging	1.000; disease causing	c.1108delG	p.E370Sfs*51	–	–	–

Y. Tsurusaki[a]
R. Yonezawa[b]
M. Furuya[c]
G. Nishimura[d]
R. K. Pooh[e]
M. Nakashima[a]
H. Saitsu[a]
N. Miyake[a]
S. Saito[b]
N. Matsumoto[a]

[a]Department of Human Genetics, Yokohama City Graduate School of Medicine, Yokohama, Japan,
[b]Department of Obstetrics and Gynecology, University of Toyama, Toyama, Japan,
[c]Department of Molecular Pathology, Yokohama City Graduate School of Medicine, Yokohama, Japan,
[d]Department of Pediatric Imaging, Tokyo Metropolitan Children's Medical Center, Fuchu, Japan, and
[e]Division of Fetal Imaging Diagnosis, CRIFM Clinical Research Institute of Fetal Medicine PMC, Osaka, Japan

References

1. Walczak-Sztulpa J, Eggenschwiler J, Osborn D et al. Cranioectodermal dysplasia, sensenbrenner syndrome, is a ciliopathy caused by mutations in the IFT122 gene. Am J Hum Genet 2010: 86: 949–956.
2. Saitsu H, Nishimura T, Muramatsu K et al. De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. Nat Genet 2013: 45: 445–449.
3. Eleftheriades M, Iavazzo C, Manolakos E et al. Recurrent short rib polydactyly syndrome. J Obstet Gynaecol 2013: 33: 14–16.
4. Cortellino S, Wang C, Wang B et al. Defective ciliogenesis, embryonic lethality and severe impairment of the Sonic Hedgehog pathway caused by inactivation of the mouse complex A intraflagellar transport gene Ift122/Wdr10, partially overlapping with the DNA repair gene Med1/Mbd4. Dev Biol 2009: 325: 225–237.
5. Bhuiyan ZA, Momenah TS, Gong Q et al. Recurrent intrauterine fetal loss due to near absence of HERG: clinical and functional characterization of a homozygous nonsense HERG Q1070X mutation. Heart Rhythm 2008: 5: 553–561.

Correspondence:
Naomichi Matsumoto
Department of Human Genetics
Yokohama City Graduate School of Medicine
3-9 Fukuura, Kanazawa-ku
Yokohama 236-0004
Japan
Tel.: +81 45 787 2606
Fax: +81 45 786 5219
e-mail: naomat@yokohama-cu.ac.jp

594

informa
healthcare

Does surgery improve live birth rates in patients with recurrent miscarriage caused by uterine anomalies?

B.L.

[AQ1] M. Sugiura-Ogasawara[1], B.-L. Lin[2], K. Aoki[3], T. Maruyama[4], M. Nakatsuka[5], N. Ozawa[6], T. Sugi[7], T. Takeshita[8] & M. Nishida[9]

[AQ2] [1]Department of Obstetrics and Gynecology, Nagoya City University, Graduate School of Medical Sciences, [2]Department of Obstetrics and Gynecology, Kawasaki Municipal Hospital, Kawasaki, [3]Aoki Ladies Clinic, Nagoya, [4]Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, [5]Faculty of Health Sciences, Okayama University Medical School, Okayama, [6]Department of Obstetrics and Gynecology, Tokyo Medical Center, Tokyo, [7]Sugi Women's Clinic Laboratory for Recurrent Pregnancy Loss, Kanagawa, [8]Department of Obstetrics and Gynecology, Nippon Medical School, Tokyo and [9]Department of Obstetrics and Gynecology, National Hospital Organization Kasumigaura Medical Center, Ibaragi, Japan

We found that congenital uterine anomalies have a negative impact on reproductive outcome in recurrent-miscarriage couples, being associated with further miscarriage with a normal embryonic karyotype. There has been no study comparing live birth rates between patients with and without surgery. We conducted a prospective study to prove that surgery for a bicornuate or septate uterus might improve the live birth rate. A total of 170 patients with congenital uterine anomalies suffering two or more miscarriages were examined. The live birth rate after ascertainment of anomalies, cumulative live birth rate and infertility rate, were compared between patients with and without surgery. In patients with a septate uterus, the live birth rate (81.3%) at the first pregnancy after ascertainment of anomalies with surgery tended to be higher than that (61.5%) in those without surgery. The infertility rates were similar in both groups, while the cumulative live birth rate (76.1%) tended to be higher than without surgery (60.0%). Surgery showed no benefit in patients with a bicornuate uterus for having a baby, but tended to decrease the preterm birth rate and the low birth weight. The possibility that surgery has benefits for having a baby in patients with a septate uterus suffering recurrent miscarriage could not be excluded.

Keywords: Bicornuate uterus, congenital uterine anomaly, metroplasty, recurrent pregnancy loss, septate uterus

Introduction

Established causes of recurrent miscarriages are antiphospholipid ~~antibody~~ syndrome (APS), abnormal chromosomes in either partner and in particular, translocations and chromosomal abnormalities in the embryo (Farquharson et al. 1984; Ogasawara et al. 2000; Sugiura-Ogasawara et al. 2004). We found that congenital uterine anomalies have a negative impact on reproductive outcome in recurrent-miscarriage couples, being associated with further miscarriage with a normal embryonic karyotype (Sugiura-Ogasawara et al. 2010).

Affected patients are offered surgery in an attempt to restore the uterine anatomy, as shown in the literature (Jones and Jones 1953; Strassmann 1961; Goldenberg et al. 1995; Jacobsen and DeCherney 1997; Grimbizis et al. 1998; Karande and Gleicher 1999; Lee and Hickok 2000; Patton et al. 2004; Kormayos et al. 2006). However, these studies are biased due to the fact that either there were no controls, or patients with recurrent miscarriage treated by surgery served as their own controls.

In our previous study, 78% of patients with anomalies who did not undergo surgery could give live birth cumulatively (Sugiura-Ogasawara et al. 2010). The general assumption is that operations can increase successful pregnancies, but there have been no randomised control trials comparing pregnancy outcome between cases with and without surgery in patients with a history of recurrent miscarriage (Kowalik et al. 2011).

Since information concerning prognosis in such women is limited and there has been no case–control study comparing live birth rates between patients with and without surgery for bicornuate or septate uterus in individuals with a history of recurrent miscarriage, despite regular performance of this technique worldwide, the present multicentre investigation was performed. This was the first prospective study comparing the live birth rate between patients with and those without surgery.

Materials and methods

Patients

This prospective study was performed in Nagoya City University Hospital, Kawasaki Municipal Hospital, Aoki Ladies Clinic, Hirosaki University Hospital, Keio University Hospital, Okayama University Hospital, Tokyo Medical Center, Toyama University Hospital, Sugi Women's Clinic, Nippon Medical School Hospital and National Hospital Organization Kasumigaura Medical Center. Patients with a history of ≥ 2 (2–9) consecutive miscarriages or ≥ 1 stillbirth, who visited the hospitals during the period between January 2003 and June 2009, were enrolled in this study.

Hysterosalpingography (HSG), transvaginal ultrasound (US), chromosome analysis for both partners, determination of aPL,

and blood tests for hyperthyroidism, diabetes mellitus and hyper-prolactinaemia were performed for all patients before their subsequent pregnancy.

HSG and/or 2D US were used as the initial screening tools. Laparoscopy/laparotomy and/or MRI were performed to ascertain the type of anomaly (investigating both the uterine cavity and the external uterine contours) in accordance with the American Fertility Society classification of Müllerian anomalies (American Fertility Society 1988; Pellerito et al. 1992; Woelfer et al. 2001). Tompkin's Index >25% was the criterion used to distinguish between arcuate uterus and mild septate or bicornuate uterus (Tompkins 1962). A bicornuate uterus was distinguished from a septate uterus when a fundal indentation dividing the two cornua was detectable (American Fertility Society 1988).

Surgery

Patients with a bicornuate uterus wishing surgical treatment before subsequent pregnancies underwent a Strassmann metroplasty mainly in the National Hospital Organization Kasumigaura Medical Center (Strassmann 1961). The majority of patients with a septate uterus underwent transcervical resection (TCR), or a Jones modified metroplasty in the Kawasaki Municipal Hospital, the National Hospital Organization Kasumigaura Medical Center and Nippon Medical School Hospital (Jones and Jones 1953; Goldenberg et al. 1995).

Follow-up

The outcomes of patients with a bicornuate or septate uterus were followed up by telephone as far as possible. In the present study: (1) the first pregnancy outcome after ascertainment of anomalies was determined for both septate and bicornuate uterus cases, comparing patients with or without surgical correction; (2) the infertility rates were compared between patients with and without surgery; infertility was determined as not pregnant after 1 year of trying to conceive; (3) all pregnancy outcomes after systematic examination were assessed and the final live birth rate of the patients, including infertile patients calculated.

The study was approved by the Research Ethics Committee at the Nagoya City University Medical School.

The analysis was carried out using the SPSS for Windows, version 19.0. Multivariate logistic analyses were performed to examine the association of a subsequent live birth with the presence of surgery, age and the number of previous miscarriages. A value of $p < 0.05$ was considered to be statistically significant.

Results

A total of 227 patients had congenital uterine anomalies: 56 had partial or complete bicornis unicolli; 145 a septum; 12 a unicornis and 14 a didelphys. None of them had hypoplasias/agenesis or DES drug-related anomalies. One patient with a bicornuate uterus also had a translocation in one partner.

A total of 170 patients with a bicornuate or septate uterus could be followed up. Baseline characteristics are shown in Table I. We found no differences between the two groups.

Subsequent pregnancy outcomes are summarised in Table II. A total of 78 of the 96 pregnant patients with a septate uterus (81.3%) treated with surgery had a successful outcome, while this was the case for eight of the 13 (61.5%) without surgery at the subsequent first pregnancy (difference not significant). Eight of 12 pregnant patients with a bicornuate uterus (66.7%) treated with surgery and 22 of 28 patients (78.6%) without surgery gave a live birth, respectively (not significant).

In total, 83 of 96 (86.5%) patients with a septate uterus treated with surgery; nine of 13 (69.2%) patients with a septate uterus and without surgery; nine of 12 (75.0%) patients with a bicornuate uterus treated with surgery and 24 of 28 (85.7%) patients without surgery could have a living baby cumulatively within the follow-up period (not significant).

Infertility rates for patients with a septate uterus treated with and without surgery, and with a bicornuate uterus treated with and without surgery were 11.9% vs 13.3% and 14.3% vs 6.3%, respectively. There were no significant differences.

Final live birth rates per person including infertility rates were 76.1% vs 60.0% in septate cases and 64.3% vs 75.0% in bicornuate cases, respectively. Regarding a septate uterus, the live birth rate of patients who received surgery tended to be higher than that of patients without surgery after including infertile patients. Age at diagnosis was found to be an independent risk factor ($p = 0.013$, OR, 1.148; 95% confidence interval (CI): 1.029–1.280).

The frequency of preterm birth and low birth weight in patients without surgery tended to be higher than that in patients with surgery ($p = 0.058$, $p = 0.023$, Table III). The frequency of caesarean section in patients with surgery was significantly higher than that in patients without surgery ($p = 0.006$). However, when bicornuate and septate uterus cases were distinguished, the differences were not significant.

Discussion

The present multicentre study illustrated the possibility that surgery might be effective for increasing the chance of having a live baby in septate uterus cases suffering recurrent miscarriage. To our knowledge, this is the first study of pregnancy outcomes of patients with congenital uterine anomalies comparing surgery and no surgery groups (Kowalik et al. 2011). Although the study design was not a randomised control trial, the results are generally positive. Selection bias was relatively small because there was no difference in the baseline characteristics.

Chan et al. (2011) conducted a systematic review and concluded that the prevalence of uterine anomalies was not higher in women with infertility (8.0%; 95% CI: 5.3–12.0, $p = 0.239$) but higher in women with a history of miscarriage (13.3%; 95% CI: 8.9–20; $p = 0.011$) compared with that in an unselected

Table I. Baseline characteristics of patients with congenital uterine anomalies (mean ± SD).

	Septate ($n = 124$)			Bicornuate ($n = 46$)		
	With surgery ($n = 109$)	Without surgery ($n = 15$)	p value	With surgery ($n = 14$)	Without surgery ($n = 32$)	p value
Age (years)	32.9 ± 4.0	33.7 ± 4.0	NS	33.1 ± 4.2	31.0 ± 3.9	0.097
Previous miscarriages	2.74 ± 1.48	2.93 ± 1.16	NS	2.86 ± 2.07	2.75 ± 1.14	NS
Previous stillbirths	0.20 ± 0.49	0.13 ± 0.35	NS	0.50 ± 1.34	0.16 ± 0.51	NS
Previous live births	0.10 ± 0.38	0.13 ± 0.35	NS	0.14 ± 0.36	0.06 ± 0.25	NS

Table II. Comparison of successful pregnancy outcomes between patients with and without surgery.

	Septate (n = 124)							Bicornuate (n = 46)						
	With surgery (n = 109)		Without surgery (n = 15)		p value	OR	95% CI	With surgery (n = 14)		Without surgery (n = 32)		p value	OR	95% CI
	n	(%)	n	(%)				n	(%)	n	(%)			
Live birth rate at the first pregnancy after examination	78/96	81.3	8/13	61.5	0.289	2.034	0.547–7.556	8/12	66.7	22/28	78.6*	0.266	0.378	0.068–2.095
Infertility rate after diagnosis	13	11.9	2	13.3	NS			2	14.3	2	6.3	NS		
Cumulative live birth rate	83/96	86.5	9/13	69.2	0.100	3.081	0.871–1.157	9/12	75.0	24/28	85.7	0.610	0.614	0.094–4.007
Cumulative live birth rate per patient	83/109	76.1	9/15	60.0	0.189	2.214	0.677–7.240	9/14	64.3	24/32	75.0	0.319	0.475	0.011–2.052

*One fetus of a patient with a bicornuate uterus was terminated at 20 weeks' gestation because of a fetal anomaly. This case was excluded from the analysis. The case with both a bicornuate uterus and translocation miscarried because of embryonic unbalanced chromosomes and was also excluded from the analysis.

population (5.5%; 95% CI: 3.5–8.5). The prevalence of anomalies in women with two or more miscarriages (10.9%; 95% CI: 3.6–33.3) was not significantly different from that in women with three or more miscarriages (15.4%, 95% CI: 10.3–23, $p = 0.572$). The prevalence of arcuate uterus, as diagnosed by optimal tests, was not increased in infertile women (1.8%; 95% CI: 0.8–4.1) or in women with a history of miscarriage (2.9%; 95% CI: 0.9–9.6), as compared with that in an unselected population (3.9%; 95% CI: 2.1–7.1). Arcuate uterus seems to be a normal variant and not a uterine anomaly. Thus, we excluded patients with arcuate uterus in the present study. According to the systematic review carried out by Chan et al. (2011), the prevalence of major uterine anomalies in women with miscarriage was 10.4%. *Raza et al. 1997*

Several studies concerning the obstetric outcome after removal of a uterine septum have been reported (Goldenberg et al. 1995; Jacobsen and DeCherney 1997; Grimbizis et al. 1998; Karande and Gleicher 1999; Lee and Hickok 2000; Patton et al. 2004; Kormayos et al. 2006). Lee and Hickok (2000) described a 77.3% uncomplicated delivery rate per pregnant woman after hysteroscopic septum resection. Kormanyos et al. (2006) compared pregnancy outcome after removal of septum between cases with and without a residual septum in patients with a history of two or three miscarriages and concluded the live birth rate in cases with no remnant was significantly higher. The live birth rate per pregnancy after surgery was reported to be 68–80%. However, the live birth rate per patient could be calculated to be 54–64% (Sugiura-Ogasawara et al. 2013). Both live birth rates were lower than those (81.3% per pregnancy and 76.1% per patient) in our present study.

Surgery here improved the live birth rate of patients with a septate uterus from 61.5% to 81.3%, though the difference was not significant. One of the most important complications of surgery is speculated to be infertility caused by operative adhesion. However, the infertility rates were found to be similar to that without surgery in the present study. The cumulative live birth rate also tended to be higher after including the infertile cases. Furthermore, the rates for preterm birth and low birth weight were significantly higher in patients without surgery.

A recent cohort study indicated that the presence of an anomaly was associated with preterm birth < 34 weeks (adjusted odds ratio, OR, 7.4; 95% CI: 4.8–11.4; $p < 0.01$); preterm birth < 37 weeks (OR, 5.9, 95% CI: 4.3–8.1; $p < 0.01$); primary non-breech caesarean delivery (OR, 2.6; 95% CI: 1.7–4.0; $p < 0.01$); preterm premature rupture of membranes (OR, 3.2; 95% CI: 1.8–5.6; $p < 0.01$) and breech presentation (OR, 8.6; 95% CI: 6.2–12.0; $p < 0.01$) (Hua et al. 2011).

Regarding a bicornuate uterus, Strassmann metroplasty was mainly performed here and surgery did not appear to influence the live birth rate or the cumulative live birth rate. Thus, surgery demonstrated no benefit in patients with a bicornuate uterus, for having a baby. While, preterm birth was less frequent in patients receiving surgery, it occurred from 32 to 35 weeks' gestation.

It proved difficult to examine the significance of the distinction between septate and bicornuate uteri because of the absence of internationally established criteria. However, it is important to distinguish between the two, especially regarding selection of surgical methods because TCR for the bicornuate uterus may cause a risk of perforation of the uterine fundus. HSG is the diagnostic modality which most often leads to a tentative diagnosis

Table III. Preterm birth, low birth weight and caesarean section rates in patients with a bicornuate or a septate uterus.

	Bicornuate or septate					Septate					Bicornuate				
	With surgery		Without surgery		p value	With surgery		Without surgery		p value	With surgery		Without surgery		p value
	n	(%)	n	(%)		n	(%)	n	(%)		n	(%)	n	(%)	
Preterm birth	4/87	4.6	5/32	15.6	0.058	4/79*	5.1%	1/8	12.5	NS	0/8	0	4/24	16.7	NS
Low birth weight	4/87	4.6	6/32	18.8	0.023	4/79	5.1	1/8	12.5	NS	0/8	0	5/24	20.8	NS
Caesarean section	54/87	62.1	11/32	34.4	0.006	49/79	62.0	5/8	62.5	NS	5/8	62.5	6/24	22.7	0.068
Other remarks						Abruptio placenta (31 w, 37 w)									

*Four patients with twin pregnancies suffered preterm delivery and were excluded.

1 of congenital anomalies. We ascertained the type of anomaly in
2 accordance with the American Fertility Society classification of
3 Müllerian anomalies, using laparoscopy or MRI for a final diag-
4 nosis (American Fertility Society 1988). Further study is needed
5 to establish criteria based on comprehensive evidence.
6   Since the live birth rate will clearly depend on the method of
7 metroplasty and the technique of each gynaecologist, we need to
8 examine the outcome per centre, but this was hampered in this
9 case by the small sample size. The live birth rate might depend on
10 the length of the septum.
11   Congenital uterine anomalies have a negative impact
12 on reproductive outcomes in recurrent-miscarriage couples
13 (Sugiura-Ogasawara et al. 2010; Chan et al. 2011; Sugiura-
14 Ogasawara et al. 2013). Our study showed the possibility that
15 surgery might improve the live birth rate, preterm birth rate and
16 low birth weight, with no influence on the infertility rates, in
17 patients with a septate uterus. However, the difference was not
18 statistically significant. This might be due to the small number of
19 patients not treated surgically (8/13). Surgery did not appear to
20 have any benefit for having a live birth in patients with a bicornu-
21 ate uterus, although it tended to reduce preterm birth. The differ-
22 ence was not statistically significant. This might also be due to the
23 fact that there were only eight patients for analysis without sur-
24 gery. A larger cohort study or a randomised control trial should
25 now be conducted to ratify the present findings.

References

American Fertility Society. 1988. The American Fertility Society classifica-
tions of adnexal adhesions, distal tubal occlusion, tubal occlusion sec-
ondary to tubal ligation, tubal pregnancies, Mullerian anomalies and
intrauterine adhesions. Fertility and Sterility 49:944–955.
Chan YY, Jayaprakasan K, Zamora J, Thornton JG, Raine-Fenning N,
Coomarasamy A. 2011. The prevalence of congenital uterine anomalies
in selected and high-risk populations: a systematic review. Human Repro-
duction Update 17:761–771.
Farquharson RG, Pearson JF, John L. 1984. Lupus anticoagulant and preg-
nancy management. Lancet 28:228–229.
Goldenberg M, Sivan E, Sharabi Z, Mashiach S, Lipitz S, Seidman DS.
1995. Reproductive outcome following hysteroscopic management of
intrauterine septum and adhesions. Human Reproduction 10:2663–2265.
Grimbizis G, Camus M, Clasen K, Tournaye H, De Munck L, Devroey P.
1998. Hysteroscopic septum resection in patients with recurrent abor-
tions or infertility. Human Reproduction 13:1188–1193.
Hua M, Odibo AO, Longman RE, Macones GA, Roehl KA, Cahill AG.
2011. Congenital uterine anomalies and adverse pregnancy outcomes.
American Journal of Obstetrics and Gynecology 205:558.e1–e5.
Jacobsen LJ, DeCherney A. 1997. Results of conventional and hysteroscopic
surgery. Human Reproduction 12:1371–1387.
Jones HW, Jones GE. 1953. Double uterus as an etiological factor in repeated
abortion: indications for surgical repair. American Journal of Obstetrics
and Gynecology 65:325–339.
Karande VC, Gleicher N. 1999. Resection of uterine septum using gynaeco-
radiological techniques. Human Reproduction 14:1226–1229.
Kormayos Z, Molar BG, Pal A. 2006. Removal of a residual portion of uter-
ine septum I women of advanced reproductive age: obstetrics outcome.
Human Reproduction 21:1047–1051.
Kowalik CR, Goddijn M, Emanuel MH, Bongers MY, Spinder T, de Kruif JH
et al. 2011. Metroplasty versus expectant management for women with
recurrent miscarriage and a septate uterus. Cochrane Database of Sys-
tematic Reviews (6):CD008576.
Lee R, Hickok LR. 2000. Hysteroscopic treatment of the uterine septum: a
clinician's experience. American Journal of Obstetrics and Gynecology
182:1414–1420.
Ogasawara M, Aoki K, Okada S, Suzumori K. 2000. Embryonic karyotype of
abortuses in relation to the number of previous miscarriages. Fertility and
Sterility 73:300–304.
Patton PE, Novy MJ, Lee DM, Hickok LR. 2004. The diagnosis and repro-
ductive outcome after surgical treatment of the complete septate uterus,
duplicated cervix and vaginal septum. American Journal of Obstetrics
and Gynecology 190:1669–1678.
Pellerito JS, McCarthy SM, Doyle MB, Glickman MG, DeCherney AH.
1992. Diagnosis of uterine anomalies: relative accuracy of MR imaging,
endovaginal sonography, and hysterosalpingography. Radiology 183:
795–800.
Raga F, Bauset C, Remohi J, Bonilla-Musoles F, Simon C, Pellicer A. 1997.   [AQ6]
Reproductive impact of congenital Mullerian anomalies. Human Repro-
duction 12:2277–2281.
Strassmann EO. 1961. Operations for double uterus and endometrial atresia.
Clinical Obstetrics and Gynecology 4:240.
Sugiura-Ogasawara M, Ozaki Y, Kitaori T, Kumagai K, Suzuki S. 2010.
Midline uterine defect size correlated with miscarriage of euploid
embryos in recurrent cases. Fertility and Sterility 93:1983–1988.
Sugiura-Ogasawara M, Ozaki Y, Sato T, Suzumori N, Suzumori K. 2004. Poor
prognosis of recurrent aborters with either maternal or paternal recipro-
cal translocation. Fertility and Sterility 81:367–373.
Sugiura-Ogasawara M, Ozaki Y, Suzumori N. 2013. Müllerian anomalies and
recurrent miscarriage. Current Opinion in Obstetrics and Gynecology
25:293–298.
Tompkins P. 1962. Comments on the bicornuate uterus and twinning. Surgi-
cal Clinics of North America 42:1049.
Woelfer B, Salim R, Banerjee S, Elson J, Regan L, Jurkovic D. 2001. Repro-
ductive outcomes in women with congenital uterine anomalies detected
by three-dimensional ultrasound screening. Human Reproduction 98:
1099–1103.

[AQ5]
[AQ4]

Genotyping Analysis for the 46 C/T Polymorphism of Coagulation Factor XII and the Involvement of Factor XII Activity in Patients with Recurrent Pregnancy Loss

Eriko Asano[1], Takeshi Ebara[2], Chisato Yamada-Namikawa[3], Tamao Kitaori[1], Nobuhiro Suzumori[1], Kinue Katano[1], Yasuhiko Ozaki[1], Makoto Nakanishi[3], Mayumi Sugiura-Ogasawara[1]*

1. Department of Obstetrics and Gynecology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan, 2. Occupational and Environmental Health, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan, 3. Department of Biochemistry II, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan

*og.mym@med.nagoya-cu.ac.jp

Abstract

Background: Established causes of recurrent pregnancy loss (RPL) include antiphospholipid syndrome, uterine anomalies, parental chromosomal abnormalities, particularly translocations and abnormal embryonic karyotype. A systematic review concluded that coagulation factor XII (FXII) deficiency was associated with RPL. However, it could not be established whether the 46 C/T SNP of FXII or low activity of FXII was a risk factor for RPL, because of the small sample size.

Methods and Findings: We conducted a cross-sectional and cohort study in 279 patients with two or more unexplained consecutive pregnancy losses and 100 fertile women. The association between the lupus anticoagulant (LA) activity and FXII activity was examined. The frequency of the CC, CT and TT genotypes and the FXII activity were also compared between the patients and controls. Subsequent miscarriage rates among the CC, CT, TT genotypes and according to the FXII activity was examined. LA was associated with reduced FXII activity. The CT, but not the TT, genotype was confirmed to be a risk factor for RPL in the cross-sectional study using multivariate logistic regression analysis (OR, 2.8; 95% CI, 1.37–5.85). The plasma FXII activity in the patients was similar to that in the controls. Neither low FXII activity nor the CT genotype predicted the subsequent pregnancy outcome in the cohort study. On the other hand, and intermediate FXII activity level of 85–101% was predictive of subsequent miscarriage.

Conclusions: Low FXII activity was not associated with RPL. The FXII gene was found to be one of the significant susceptibility genes for RPL, similar to the FV Leiden mutation. However, the clinical influence of the CT genotype might be relatively small, because the presence/absence of this genotype did not have any predictive value for the subsequent pregnancy outcome. This was the first study indicating the influence of *FXII 46C/T* on further pregnancy outcomes.

Introduction

Recurrent miscarriage (RM) is classically defined as three or more consecutive miscarriage [1]. However, many researchers have now revised the definition to two or more pregnancy losses, namely recurrent pregnancy loss (RPL), because of the recent increase in the prevalence of childless couples. The estimated incidence of RM and RPL are 1% and 5%, respectively [1]. Established causes of RPL include antiphospholipid syndrome (APS), uterine anomalies, and chromosomal abnormalities, particularly translocations, in either partner [1–4]. However, according to reports, in about a half of the cases seen at research centers, the cause remains unexplained despite conventional examinations conducted to identify the cause [5, 6]. Recently, we found that an abnormal embryonic karyotype was the most frequent cause of 2 or more RPL, accounting for as high as 41% of all the cases [7].

APS, acquired thrombophilia, is the only one treatable cause of RPL, and combined low-dose aspirin and heparin treatment having been shown to improve the live birth rate in patients with APS [8, 9]. Heritable thrombophilia has been reported to be associated with RM [10, 11].

Coagulation factor XII (FXII) is an 80-kDa serine protease that is involved in the initiation of the intrinsic pathway of the coagulation cascade. It is converted to its active form (activated factor XII, XIIa) by limited proteolysis [12], either by autoactivation on the surface of negatively charged compounds or by kallikrein [13]. Although FXII deficiency is associated with a prolonged activated partial thromboplastin time (aPTT), it is not associated with increased bleeding [14]. A C/T polymorphism has been identified in the promoter region of the *FXII* gene at nt46. The 46C/T polymorphism creates a new initiation codon (ATG) for transcription of the mRNA and a frameshift that produces a truncated protein. The T allele destroys the Kozak's consensus sequence (GCCAGCCATGG) for translation initiation signaling and prevents proper recognition of the translation initiation site. The T allele is therefore well-known to be associated with low plasma levels of factor XII [15]. The existence of associations between low FXII activity levels and thrombotic outcomes has been under debate for more than a decade.

We previously reported that the miscarriage rate of patients with low FXII activity (less than 39%) was significantly higher than that of patients with normal

FXII activity [16]. We also found that the frequency of the T allele did not differ between the women with a history of RPL and control fertile women [17]. However, the association between the C/T polymorphism or FXII activity and RPL could not be clearly elucidated, because the sample size was relatively small.

Thus, we conducted this cross-sectional and cohort study to determine the clinical significance of C/T polymorphism and FXII activity. We examined the association between 46C/T polymorphism and RPL, and between FXII activity and RPL in the cross-sectional study. We examined whether 46C/T polymorphism or FXII activity influenced the subsequent miscarriage rate in the cohort study. This was the first study to investigate the influence of FXII SNP on the subsequent pregnancy outcome.

Materials and Methods

Patients and controls

All patients were seen at Nagoya City University Hospital between September 2008 and July 2012. The study group consisted of 279 Japanese women with two or more consecutive pregnancy losses.

All patients underwent systematic examination, including hysterosalpingography, chromosome analysis of both partners, determination of aPL, including lupus anticoagulant (LA), by 5x-diluted aPTT, diluted Russel's viper venom time (RVVT) and β2 glycoprotein I-dependent anticardiolipin antibody determination (β2GPI-aCL), and blood tests for hypothyroidism and diabetes mellitus, before a subsequent pregnancy [18]. Criteria for exclusion from the analyses included the presence of uterine anomalies and chromosomal abnormalities in either partner. Patients with a history of thromboembolic events, pre-eclampsia, or abruptio placentae were also not included. The plasma samples for measurement of the FXII levels were obtained from the patients during the high phase of the basal body temperature (BBT).

Nine patients were positive for LA and 8 were positive for β2GPI-aCL. Of the 17, 7 patients were diagnosed as having APS, based on the persistence of the aPLs for more than 12 weeks.

Subsequent pregnancies of all patients were followed up until February 2013. Gestational age was calculated from BBT charts. Ultrasonography was performed once a week from 4 to 8 weeks of gestation. Dilation and curettage was performed in patients diagnosed as having miscarriage. A part of the villi was cultured, and the cells were harvested after 6–22 days of cultivation for chromosomal analysis using the standard G-banding technique.

Furthermore, 100 women with at least one child and no history of infertility or miscarriage were examined as controls. The control subjects consisted of 26 medical staff and 74 patients with dysplasia of the uterine cervix recruited from Nagoya City University Hospital from April to July 2013. None of the patients or controls were receiving any medication or were pregnant at the time of the study.

— 127 —

Ethics statement

This study was conducted with the approval of the Research Ethics Committee of Nagoya City University Graduate School of Medical Sciences. Each patient provided written consent after receiving a thorough explanation about the purpose of the study and the methods to be employed.

Cross-sectional study

The FXII activity was compared between the 17 patients with aPLs and 262 patients without aPLs in the cohort with RPL. The 17 patients with aPLs were excluded from further analysis. The characteristics of the 262 patients and 100 controls are shown in Table 1.

The allele frequencies of the CC, CT, TT genotypes of the *FXII* gene and FXII activity were compared between the 262 patients and 100 controls. We analyzed the data separately for the patients with a history of 3 or more early miscarriages before 10 weeks of gestation and those with a history of intrauterine fetal death (IUFD) in this cross-sectional study.

Cohort study

In the present cohort, the subsequent miscarriage rate was compared among the untreated 101 patients with a history of 3 or more early miscarriage with the CC, CT or TT genotype and according to the FXII activity.

A total of 39 of the 262 patients received heparin plus aspirin or aspirin alone in deference to the patient's wishes even after she has been provided information that aspirin or heparin had, in general, no effect on the live birth rate in cases of unexplained recurrent miscarriage [19]. These patients were excluded from the cohort study.

Statistical Analyses

The FXII activity between patients with and without aPLs was compared by student t-test.

The FXII activity was compared according to the genotype by one-way analysis of variance (ANOVA) and Tukey's multiple comparison test. The allele frequency was compared by the chi-squared test. Pearson's correlation coefficient was calculated between the aPTT and FXII activity, and between the age and FXII activity.

Multivariate logistic regression analyses were performed to examine the association of subsequent miscarriage, after adjusting for age and the number of previous miscarriages. FXII activity levels were categorized as high, normal or low using the 90th percentile, 95th percentile and 99th percentile of the values in the controls. Furthermore, the FXII activity levels were also was categorized as high, normal and low according to the CC, CT and TT genotype using the 90th

Table 1. Genotype and FXII activity in 17 patients with antiphospholipid antibodies.

	LA-aPTT	LA-RVVT	β2GPI dependent aCL	genotype	XII activity (%)
LA-aPTT-positive patients	9.8	negative	negative	CT	50
	8.7	negative	negative	CT	54
	8.3	negative	negative	CT	56
	8.2	negative	negative	CT	107
	10.9	negative	negative	TT	54
	9	negative	negative	TT	50
	8.1	negative	negative	TT	57
	8	1.3	negative	TT	53
	7.4	negative	negative	TT	65
Mean (SD) value					60.7 (17.9)
β2GPI-aCL-positive patients	negative	negative	4.6	CT	111
	negative	negative	2.8	CT	116
	negative	negative	2.4	CT	92
	negative	negative	2	CT	153
	negative	negative	10.7	TT	54
	negative	negative	7.6	TT	58
	negative	negative	5.4	TT	63
	negative	negative	2.3	TT	51
Mean (SD) value					87.3 (37.0)

10–90th percentile of FXII activity according to CC, CT and TT genotype were 101–141, 72–120 and 46–77.

percentile of the values in the controls. The FXII activity levels were also categorized into quartiles of the patients.

For the post-hoc power analysis of the genotype frequency, we used a total of 362 subjects at an α of 0.05.

All the analyses were carried out using the statistical software SPSS, Version 21. $P < 0.05$ was considered to denote statistical significance.

Genetic Analysis

Venous blood samples were collected in tubes containing K2 ethylenediamine tetraacetic acid and applied to genomic DNA extracting columns (QIAmp DNA blood Midi; Qiagen, Tokyo, Japan) according to the manufacturer's protocol. Polymerase chain reaction (PCR) was performed on genomic DNA samples using a Phusion High-Fidelity DNA Polymerase (NEW ENGLAND BioLabs, Finland). One μL (about 10 ng) solution (DNA preparation) was used as a template for the PCR. Exon 1 of the *FXII* gene was amplified by PCR using the sense and antisense primers 5′ CCAGTCCCACTATCTAGAAAAG-3′ and 5′ ATGGCTCATGGCTGT-GATAG-3′, respectively. After initial denaturation at 98°C for 30 seconds, 35 cycles (98°C for 10 seconds, 61.9°C for 30 seconds, and 72°C for 15 seconds) and final extension at 72°C for 5 minutes were used to amplify 369-base pair products.

—129—

The substitution of 46C to T substitution is located 4 bases upstream from the translation initiation codon ATG, a region corresponding to the CseI (New Engrand BioLabs, Beverly, MA) restriction site (GACGC), which is therefore destroyed (46T). To analyze the polymorphism by electrophoresis, the samples were separated on 2% agarose gels (Takara, Japan) after enzyme digestion and stained with ethidium bromide.

To confirm the genotype, purified templates were sequenced with the BigDye Terminator v3.1 Cycle Sequencing kit (ABI Prism, Applied Biosystems, Foster City, CA, USA) on a 3100 automated sequencer.

Factor XII activity

Plasma samples were prepared in tubes containing 3.2% sodium citrate by centrifugation at 4°C at 3,000 rpm for 10 minutes. The plasma samples were then stored at −40°C until use. The FXII activity was determined by a clotting assay using coagulation factor XII kits (HemosIL, Instrumentation Laboratory, USA). A major domestic laboratory company performed the FXII activity measurements. The intra-assay CV for the high activity control was 2.98%, and that for the low activity control was 4.03%.

Results

Nine patients were positive for LA-aPTT and one was positive for both LA-aPTT and LA-RVVT (Table 1). The FXII activity in patients with LA was significantly lower than in the patients without LA (60.7 ± 17.9% vs. 83.4 ± 29.3%; p=0.02). FXII activity in 8 patients with β2GPI-aCL alone was 87.3 ± 37.0 (not significantly different). Thus, we excluded the 17 patients with aPLs from the following comparison.

The mean age of the fertile controls was higher than that of the patients (p=0.002, Table 2). Eleven patients gave a history of previous intrauterine fetal death (IUFD). Secondary RPL was 18.7%.

The results of the cross-sectional study are shown in Table 3. The wild-type (CC), heterozygote (CT) and homozygote (TT) alleles for the *FXII* gene were observed in 22 (8.4%), 139 (53.1%) and 101 (38.5%) patients with RPL vs. 17 (17.0%), 38 (38.0%) and 45 (45.0%) controls. The frequency of CT in the patients with RPL was significantly higher than that in the controls (OR, 2.83; 95% CI, 1.37–5.85; p=0.005). The frequency of TT in the patients also tended to be higher than that in the controls. The statistical power for the frequency of CT was sufficient (1−β=0.79), while that for the frequency of TT was insufficient (1−β=0.31). The frequency of CT in the patients with 3 or more early miscarriage tended to be higher than that in the controls (OR, 2.32; 95% CI, 0.98–5.49; p=0.06).

In regard with the C/T ratio, the frequency of T allele in the patients was similar to that of controls.

Table 2. Characteristics of 262 patients with a history of recurrent pregnancy losses and 100 control healthy women with a history of live birth.

	Controls	2 or more	3 or more
No. of patients	100	262	121
Mean age (SD)	35.2 (4.7) 21–42	33.5 (4.6) 21–45	33.8 (4.8) 21–45
Mean (SD) No. of previous miscarriages	0	2.58 (0.79)	3.26 (0.69)
2		141	-
3		98	98
4		19	19
5		1	1
6		2	2
8		1	1
Mean (SD) No. of previous intrauterine fetal death	0	0.05 (0.23)	0.04 (0.24)
0		251 (95.8%)	117 (96.7%)
1–2		11 (4.2%)	4 (3.3%)
Mean (SD) No. of previous live births	1.6 (0.7)	0.20 (0.44)	0.26 (0.48)
Primary	0	213 (81.3%)	91 (75.2%)
Secondary	100	49 (18.7%)	30 (24.8%)

doi:10.1371/journal.pone.0114452.t002

The differences in the activity levels between the CC and CT (p<0.001), CT and TT (p<0.001) and CC and TT (p<0.001) genotypes in the patients, and between the CC and CT (p<0.001), CT and TT (p<0.001) CC and TT (p<0.001)

Table 3. Cross-sectional study: The frequencies of the CC, CT and TT genotypes and the factor XII activities in the 262 patients and 100 controls.

	The frequencies of the CC, CT and TT genotypes						
Genotype	Control n (%)	Patients with 2 or more miscarriage		Patients with 3 or more early miscarriage		Patients with a history of IUFD	
Total	100	262	OR (95% CI)	117	OR (95% CI)	11	OR (95% CI)
CC	17 (17)	22 (8.4)	reference	11 (9.4)	reference	0	reference
CT	38 (38)	139 (53.1)	**2.83 (1.37–5.85) 0.005**	57 (48.7)	2.32 (0.98–5.49) 0.056	8 (72.7)	-
TT	45 (45)	101 (38.5)	1.73 (0.84–3.58) 0.136	49 (41.9)	1.68 (0.71–3.98) 0.235	3 (27.3)	-
CT, TT	83 (83)	240 (91.6)	**2.23 (1.13–4.41) 0.021**	106 (90.6)	1.97 (0.88–4.44) 0.100	11 (100)	-
C/T ratio	0.36/0.64	0.34/0.66		0.34/0.66		0.36/0.64	
	The factor XII activities: mean (SD) value and range						
Total XII activity	83.8 (28.6) 40–143	83.8 (29.1) 37–178		80.9 (29.0) 37–145		71.8 (14.4) 51–94	
CC	123.1 (14.3) 97–143	126.1 (17.7) 87–160		125.2 (14.1) 97–143		-	
CT	94.3 (18.5) 55–129	89.2 (25.8) 37–178		89.9 (22.4) 37–145		74.5 (12.5) 61–94	
TT	60.0 (14.5) 40–115	65.8 (21.6) 37–139		61.6 (17.8) 37–137		64.7 (19.5) 51–87	

doi:10.1371/journal.pone.0114452.t003

—131—

genotypes in the controls were significant. ANOVA revealed no significant difference in the mean FXII activity levels between the patients and controls. Twenty-seven of the 262 (10.3%) patients and 10 of the 100 (10%) controls showed decreased FXII activity (<50%), the difference in the percentage not being significant. A weak correlation coefficient between the aPTT and FXII activity was observed (r=−0.479). There was no correlation between the FXII activity and age.

The subsequent miscarriage rate in patients with RPL was 26.0% (68/262). A total of 32 (47.1%) miscarried conceptuses could be karyotyped, of which, 15 (46.9%) had a normal karyotype and 17 (53.1%) had an abnormal karyotype.

Association between the subsequent miscarriage rate and the *FXII* genotype or FXII activity in the 101 untreated patients with a history of RM was analyzed (Table 4). The miscarriage rates were 30.0%, 21.2% and 30.8% in the patients with the CC, CT and TT genotypes, respectively. According to the results of the logistic regression analysis, there was no increase in the miscarriage rate associated with the presence of CT and TT as compared to that associated with the presence of CC. A similar result was obtained after excluding cases with miscarriage caused by an abnormal embryonic karyotype.

The logistic regression analysis also showed no significant increase in the miscarriage rate associated with low or high FXII activity levels, classified using the cutoff values of 10–90th percentile, 5–95th percentile and 1–99th percentile of the control values (Table 4). The frequencies obtained using the latter two cutoffs seemed to be insufficient to detect any significant differences (not shown). The multivariable analyses showed no significant increase in the miscarriage rate associated with FXII activity levels even after excluding cases with an abnormal embryonic karyotype.

Furthermore, when the FXII activity was categorized into high, normal or low classified using the 10–90th percentile of the control values for each of the CC, CT and TT genotypes, the logistic regression analysis showed significant increase in the miscarriage rate associated with high FXII activity level (OR, 5.65; 95% CI, 1.24–25.64; p=0.03). However, the difference disappeared after exclusion of cases with an abnormal embryonic karyotype. When the FXII activity was categorized into quartiles, the intermediate level, that is, a FXII activity level of 85–101%, predicted subsequent miscarriage (OR, 4.65; 95% CI, 1.06–20.4; p=0.04). The result remained significant after excluding cases with an abnormal embryonic karyotype.

Discussion

The FXII activity in the 9 patients with LA was significantly lower than that in the patients without LA in the present study. This was in line with the results of Gallimore's study [20]. LA might include antibodies to factor XII, as an association has been reported between the presence of antibodies to factor XII and recurrent fetal loss in patients with APS [21]. In the present study, there was no

Table 4. Cohort study: Subsequent miscarriage rate according to the genotype and FXII activity in 101 untreated patients with a history of recurrent miscarriage.

		Miscarriage rate	Crude analysis		Multivariable Logistic regression		Miscarriage rate excluding abnormal embryonic karyotype	Crude analysis		Multivariable Logistic regression	
			OR [a] (95% CI [b])	P-value	OR (95% CI)	P-value		OR (95% CI)	P-value	OR (95%CI)	P-value
Genotype	CC	30.0% (3/10)	reference		reference		22.2% (2/9)	reference		reference	
	CT	21.2% (11/52)	0.40 (0.08–1.96)	0.26	0.40 (0.07–1.96)	0.26	19.6% (10/51)	0.86 (0.15–4.76)	0.86	0.50 (0.08–3.06)	0.46
	TT	30.8% (12/39)	1.04 (0.23–4.72)	0.96	0.79 (0.17–3.73)	0.77	20.6% (7/34)	0.90 (0.15–5.38)	0.92	0.68 (0.11–4.18)	0.68
FXII activity (10–90th percentile)[c]	Normal	31.3% (22/83)	reference		reference		20.8% (16/77)	reference		reference	
	High	37.5% (3/8)	1.66 (0.37–7.52)	0.51	1.96 (0.41–9.35)	0.40	28.6% (2/7)	1.52 (0.27–8.62)	0.63	1.84 (0.31–10.99)	0.50
	Low	10.0% (1/10)	0.29 (0.04–2.57)	0.28	0.35 (0.04–3.01)	0.34	10.0% (1/10)	0.42 (0.05–3.60)	0.43	0.50 (0.06–4.31)	0.52
Genotype and FXII activity (10–90th percentile)[d]	Normal	25.3% (19/75)	reference		reference		21.1% (15/71)	reference		reference	
	High	66.7% (6/9)	**5.88 (1.34–25.64)**	**0.02**	**5.65 (1.24–25.64)**	**0.03**	50.0% (3/6)	7.75 (0.68–20.41)	0.28	4.22 (0.73–24.4)	0.11
	Low	5.9% (1/17)	0.18 (0.02–1.48)	0.11	0.20 (0.02–1.62)	0.13	5.9% (1/17)	0.23 (0.03–1.90)	0.17	0.24 (0.03–2.07)	0.24
FXII activity (quartile)	–56	10.3% (3/29)	reference		reference		7.1% (2/28)	reference		reference	
	57–84	31.8% (7/22)	4.05 (0.91–18.18)	0.07	3.60 (0.78–16.40)	0.10	25.0% (5/20)	4.33 (0.75–25.00)	0.10	3.86 (0.64–23.26)	0.14
	85–101	36.0% (9/25)	**4.88 (1.15–20.83)**	**0.03**	**4.67 (1.06–20.41)**	**0.04**	33.3% (8/24)	**6.49 (1.22–34.48)**	**0.03**	**6.37 (1.15–34.48)**	**0.03**
	102–	28.0% (7/25)	3.37 (0.77–14.71)	0.11	3.23 (0.71–14.49)	0.13	18.2% (4/22)	2.89 (0.48–17.54)	0.25	2.76 (0.44–17.54)	0.28

a; odds ratio, b; confidence interval, c; Normal 50–127, High 128–, Low -49,
d; CC 101–141, CT 72–120, TT 46–77.

doi:10.1371/journal.pone.0114452.t004

difference in the FXII activity levels between the patients and controls after patients with LA were excluded.

In our previous study, we failed to show an association between LA and reduced FXII activity levels because we compared only patients with the TT genotype [17]. We previously reported that low FXII activity, but not an associated common genetic polymorphism, 46C/T, was linked to RPL [17]. A systematic review concluded that FXII deficiency is associated with RM [22]. Pauer et al. reported that 10 of 67 women with primary recurrent abortion (14.9%) and 4 of 33 women (12.1%) with secondary recurrent abortion had reduced factor XII activity (<60%), while all controls had normal FXII activity [23]. However, they checked for only anticardiolipin antibody, and not LA. These results could be attributable to the inclusion of patients with LA.

Low levels of FXII was confirmed not to influence the subsequent miscarriage rate when the cutoff values were based on the 90th percentile, 95th percentile and 99th percentile of the control values. We previously reported that the miscarriage rate in patients with low FXII activity levels (less than 39%) was significantly higher than that in the patients with normal activity levels [16]. The sample size in our previous study was relatively small, because 4 of the 5 untreated patients with FXII activity levels of less than 39% developed miscarriage. The present study included the largest sample size, and was the first prospective cohort study.

CT genotype, but not the TT genotype was confirmed to be a risk factor for RM. We found no association between 46C/T polymorphism and RPL in a previous study, because the frequency of this SNP was similar between the patients and controls (0.31/0/69 and 0.31/0.69) [17]. We did not conduct comparisons according to the genotype distribution, although the frequencies of CC, CT and TT in the patients and controls were 9.6%, 43.4% and 47.0% and 16.4%, 29.9% and 53.7%, respectively, in our previous study, being quite similar to those in the present study.

Walch et al. demonstrated that the genotype distribution was not significantly different between a RM group of 212 patients and a control group of 149 women in Middle-European Caucasian population [24]. It is speculated that the distribution of the risk alleles might show ethnic differences.

Johnson et al. found a very weak association between myocardial infarction and the CT+TT genotype (OR 1.13, 95% CI 1.00–1.27), and suggested that this was caused by low FXII level activity because of the T allele [25]. We found a similar association between the CT+TT genotype and RPL (Table 3), however, only CT was significant, not TT. The statistical power for the frequency of CT was sufficient $(1-\beta=0.79)$. The statistical power for the frequency of TT was insufficient and $(1-\beta=0.31)$. This implies that a larger study might have possibilities to show the significant of differences for the TT genotype.

That the T allele might act via other mechanism(s), such as endothelial dysfunction, and not via low FXII activity, to induce myocardial infarction and miscarriage. LaRusch found that FXII initiates signaling to induce human umbilical vein endothelial cell proliferation, growth and angiogenesis [26]. FXII as a growth factor stimulates angiogenesis after ischemia, inflammation, and injury,

just like vascular endothelial growth factor. FXII plays various roles in vivo: FXII triggers the plasma contact system via the kallikrein kinin-system and intrinsic coagulation pathway, and zymogen FXII functions as a growth factor that mediates cell signaling leading to proliferation and stimulation of angiogenesis. FXII might have another role of maintaining pregnancy.

Low levels of FXII did not increase the subsequent miscarriage rate when the cutoff values were based on the 90th percentile, 95th percentile and 99th percentile of the control values. Activity levels of 85–101%, which fall in the second highest quartile, and not low FXII activity levels, were found to predict subsequent miscarriage. This intermediate range might correspond to the CT genotype, because the reported mean (SD) FXII activity in patients with the CT genotype is 89.2 (25.8), even though the CT genotype itself did not influence the likelihood of subsequent miscarriage.

Many cross-sectional studies have been reported on associations between polymorphism and RPL, such as 4G/4G for plasminogen activator inhibitor-1 polymorphisms (OR 11.0, 95% CI 2.3–52.4), protein Z intron F G79A polymorphism (OR 0.3, 95% CI 0.1–0.8) and Annexin A5's -1C/T (OR 2.7, 95% CI 1.0–6.7) [27–29]. However, the clinical significance could not be established because most were not cohort studies. Our cross-sectional study confirmed that variations in the ANXA5 gene upstream region, especially SNP5, were risk factors for RPL, and our cohort study concluded that the presence/absence of the ANXA5 risk allele did not have any significant predictive effect on the subsequent pregnancy outcome [30].

FXII activity level in the intermediate range, that is, 85–101% was predictive of subsequent miscarriage. The FXII activity is increased in old age, in females, during pregnancy, during intake of an oral contraceptive. The influence of age could be ignored, although all the patients were younger than the control women, because there was no correlation between the FXII activity and age in the present study. We could not measure FXII activity in duplicate. These are some limitations of the present study. Further study is needed because this was a new finding.

The CT genotype of the FXII gene was confirmed to be a risk factor for RPL, but it was not shown to serve as a reliable clinical predictor of the subsequent pregnancy outcome. Therefore, we propose that testing for this allele is not needed, as it is without clinical benefit and is an unnecessary expense.

Author Contributions

Conceived and designed the experiments: MS-O. Performed the experiments: EA CY-N MN NS. Analyzed the data: EA TE MS-O. Contributed reagents/materials/ analysis tools: TK KK YO MS-O. Wrote the paper: EA MS-O.

References

1. Branch DW, Gibson M, Silver RM (2010) Clinical Practice: Recurrent miscarriage. N Engl J Med 2010; 363: 1740–1747.

2. Farquharson RG, Pearson JF, John L (1984) Lupus anticoagulant and pregnancy management. Lancet 28: 228–229.

3. Sugiura-Ogasawara M, Ozaki Y, Sato T, Suzumori N, Suzumori K (2004) Poor prognosis of recurrent aborters with either maternal or paternal reciprocal translocation. Fertil Steril 81: 367–373.

4. Sugiura-Ogasawara M, Ozaki Y, Kitaori T, Kumagai K, Suzuki S (2010) Midline uterine defect size correlated with miscarriage of euploid embryos in recurrent cases. Fertil Steril 93: 1983–1988.

5. Clifford K, Rai R, Watson H, Regan L (1994) An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Hum Reprod 9: 1328–1332.

6. Stephenson MD (1996) Frequency of factors associated with habitual abortion in 197 couples. Fertil Steril 66: 24–29.

7. Sugiura-Ogasawara M, Ozaki Y, Katano K, Suzumori N, Kitaori T, et al. (2012) Abnormal embryonic karyotype is the most frequent cause of recurrent miscarriage. Hum Reprod 27: 2297–2303.

8. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L (1992) Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 166: 1318–1323.

9. Rai R, Cohen H, Dave M, Regan L (1997) Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 314: 253–257.

10. Preston FE, Rosendaal FR, Walker ID, Briët E, Berntorp E, et al. (1996) Increased fetal loss in women with heritable thrombophilia. Lancet 348: 913–916.

11. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, et al. (1999) Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 340: 50–52.

12. Braat EA, Dooijewaard G, Rijken DC (1999) Fibrinolytic properties of activated FXII. Eur J Biochem 263: 904–911.

13. Samuel M, Pixley RA, Villanueva MA, Colman RW, Villanieva GB (1992) Human factor XII (Hageman factor) autoactivation by dextran sulfate: circular dichroism, fluorescence, and ultraviolet difference spectroscopic studies. J Biol Chem 267: 19691–19697.

14. Lammle B, Wuillemin W, Huber I, Krauskopf M, Zurcher C, et al. (1991) Thromboembolism and bleeding tendency in congenital factor XII deficiency: a study of 74 subjects from 14 Swiss families. Thromb Haemost 65: 117–121.

15. Kanaji T, Okamura T, Osaki K, Kuroiwa M, Shimoda K, et al. (1998) A Common Genetic Polymorphism (46 C to T Substitution) in the 5′ Untranslated Region of the Coagulation Factor XII Gene Ia Associated With Low Translation Efficiency and Decrease in Plasma Factor XII Level. Blood 91: 2010–2014.

16. Ogasawara MS, Aoki K, Katano K, Ozaki Y, Suzumori K (2001) Factor XII but not protein C, protein S, antithrombin III or factor XIII as a predictor of recurrent miscarriage. Fertil Steril 75: 916–919.

17. Iinuma Y, Sugiura-Ogasawara M, Makino A, Ozaki Y, Suzumori N, et al. (2002) Coagulation factor XII activity, but not an associated common genetic polymorphism (46C/T), is linked to reccurent miscarriages. Fertil Steril 77: 353–356.

18. Ogasawara M, Aoki K, Matsuura E, Sasa H, Yagami Y (1996) Anti beta 2glycoprotein I antibodies and lupus anticoagulant in patients with recurrent pregnancy loss: prevalence and clinical significance. Lupus 5: 587–592.

19. Kaandorp SP, Goddijn M, van der Post JAM, Hutten BA, Verhoeve HR, et al. (2010) Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 362: 1586–1596.

20. Gallimore MJ, Jones DW, Winter M (1998) Factor XII determinations in the presence and absence of phospholipid antibodies. Thromb Haemost 79: 87–90.

—136—